In the wake of deep R&D cuts, Bayer flags safety concerns for a top PhIII drug

Less than a week after Bayer announced plans to carve down its internal R&D group, laying off 900 R&D staffers, the German company has tipped the market that one of its crucial late-stage development efforts has run into serious trouble.